[Form 3] Quoin Pharmaceuticals, Ltd. American Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Quoin Pharmaceuticals, Ltd. reported an initial beneficial ownership filing by Sally Bridget Lawlor, identifying her as Chief Financial Officer and a director. The filing reports ownership of 440 ADSs held directly; each ADS represents 35 ordinary shares. The transaction date triggering the filing is 08/18/2025 and the form is signed on 09/08/2025. The report includes a Power of Attorney (Exhibit 24.1).

Positive

• Officer status and ownership disclosed (CFO and director) showing regulatory transparency
• 440 ADSs reported directly, with ADS-to-share conversion clearly stated (35 ordinary shares per ADS)

Negative

• None.

Insights

Corporate Governance / SEC Compliance Analyst

TL;DR: Officer disclosed direct ownership of 440 ADSs, fulfilling Section 16 initial reporting requirements.

The filing records Sally Bridget Lawlor as Chief Financial Officer and a director and shows direct beneficial ownership of 440 ADSs. The filing clarifies ADS conversion equivalence: each ADS equals 35 ordinary shares, which defines the underlying share exposure.

Timely disclosure helps satisfy insider reporting obligations; monitor any future Form 4 filings for trades or option grants that would change holdings within the typical reporting window following changes in ownership or compensatory awards.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lawlor Sally Bridget

(Last) (First) (Middle)

C/O QUOIN PHARMACEUTICALS LTD.

42127 PLEASANT FREST COURT

(Street)

ASHBURN VA 20148

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/18/2025

3. Issuer Name and Ticker or Trading Symbol
Quoin Pharmaceuticals, Ltd. [ QNRX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
ADS	440(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The number of securities are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

Remarks:

Exhibit List - Exhibit 24.1: Power of Attorney

	/s/ Sally Bridget Lawlor	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 3 filing for Quoin Pharmaceuticals (QNRX) disclose?

The filing shows Sally Bridget Lawlor (CFO and director) beneficially owns 440 ADSs directly and states each ADS represents 35 ordinary shares.

When was the event requiring the Form 3 reported for QNRX?

The event date listed is 08/18/2025, and the Form 3 was signed on 09/08/2025.

Does the Form 3 indicate indirect ownership or derivative holdings for QNRX?

No. The filing lists direct ownership of ADSs and shows no derivative securities reported in the filing.

How many underlying ordinary shares does the reported ADS position represent?

Each ADS represents 35 ordinary shares, so 440 ADSs correspond to 15,400 ordinary shares (440 x 35).

Is there an exhibit attached to the Form 3 for QNRX?

Yes. The filing lists Exhibit 24.1: Power of Attorney.